{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T21:12:29Z","timestamp":1769029949374,"version":"3.49.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Unexplained recurrent implantation failure (URIF) represents a complex and challenging condition in reproductive medicine, while the role of non-criteria antiphospholipid syndrome antibodies in its pathogenesis remains unclear. As a non-criteria antiphospholipid syndrome antibody, anti-phosphatidylserine\/prothrombin antibodies were investigated in this study to explore their effects on oocyte quality and pregnancy outcomes in patients with unexplained recurrent implantation failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective cohort study that included 853 IVF\/ICSI cycles from patients with URIF at Peking University Third Hospital between April 2021 and April 2023, with patients stratified into positive and negative groups for anti-phosphatidylserine\/prothrombin antibodies. Propensity score matching (PSM) was conducted at a 1:3 ratio to adjust for potential confounding factors. The primary outcome was the cumulative live birth rate, and secondary outcomes included the live birth rate per transfer cycle, miscarriage rate, and oocyte quality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After PSM, no significant differences were detected between the aPS\/PT-positive and negative groups in terms of the oocyte and embryo parameters. Compared with the aPS\/PT-negative group, the positive group presented a lower cumulative live birth rate (20% vs 32.1%, p&amp;lt;0.05) and a higher miscarriage rate (41.4% vs 20.4%, p&amp;lt;0.05). After adjusting for confounding factors via binary logistic regression (for miscarriage) and multivariate Cox models (for cumulative live birth), the results revealed that aPS\/PT antibody positivity may be a potential independent risk factor for miscarriage in patients with URIF (OR = 3.753, 95% CI: 1.297-10.854, p&amp;lt;0.05), but its correlation with cumulative live birth rate was not significant (HR = 0.391, 95% CI: 0.391-1.179, p=0.170).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Anti-phosphatidylserine\/prothrombin antibody (aPS\/PT) positivity may be a risk factor for increased miscarriage rates in patients with unexplained recurrent implantation failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1731905","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:44:15Z","timestamp":1768977855000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of anti-phosphatidylserine\/prothrombin antibodies on pregnancy outcomes in patients with unexplained recurrent implantation failure: a retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Donglin","family":"Han","sequence":"first","affiliation":[{"name":"Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital","place":["Beijing, China"]},{"name":"Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiansuo","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Yang","sequence":"additional","affiliation":[{"name":"Blood Transfusion Department, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Liu","sequence":"additional","affiliation":[{"name":"Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital","place":["Beijing, China"]},{"name":"National Clinical Research Center for Obstetrics and Gynecology (Peking University Third Hospital)","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital","place":["Beijing, China"]},{"name":"State Key Laboratory of Female Fertility Promotion, Department of Obstetrics and Gynecology, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital","place":["Beijing, China"]},{"name":"Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital","place":["Beijing, China"]},{"name":"National Clinical Research Center for Obstetrics and Gynecology (Peking University Third Hospital)","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhao","sequence":"additional","affiliation":[{"name":"Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital","place":["Beijing, China"]},{"name":"Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200009)43:9<1982::AID-ANR9>3.0.CO;2-2","article-title":"Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant","volume":"43","author":"Atsumi","year":"2000","journal-title":"Arthritis Rheum"},{"key":"B2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12958-018-0414-2","article-title":"Recurrent Implantation Failure-update overview on etiology, diagnosis, treatment and future directions","volume":"16","author":"Bashiri","year":"2018","journal-title":"Reprod Biol Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/gco.0b013e3283294879","article-title":"Is there a role of autoimmunity in implantation failure after in-vitro fertilization","volume":"21","author":"Cline","year":"2009","journal-title":"Curr Opin Obstet Gynecol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.rbmo.2013.08.011","article-title":"Recurrent implantation failure: definition and management","volume":"28","author":"Coughlan","year":"2014","journal-title":"Reprod BioMed Online"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac327","article-title":"Anti-phosphatidylserine\/prothrombin antibodies and thrombosis associate positively with HLA-DRB1*13 and negatively with HLA-DRB1*03 in SLE","volume":"62","author":"Elbagir","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1515\/JPM.2009.061","article-title":"Progesterone - induced blocking factor (PIBF) and Th(1)\/Th(2) cytokine in women with threatened spontaneous abortion","volume":"37","author":"Hudi\u0107","year":"2009","journal-title":"J Perinat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2019.07.006","article-title":"aCL\/\u03b2(2)GPI and aPS\/PT show synergic thrombogenic effects in suppressing anticoagulant activity of APC and stimulating tissue factor expression and TNF-\u03b1 secretion by mononuclear cells","volume":"181","author":"Kaneshige","year":"2019","journal-title":"Thromb Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dez120","article-title":"What is the prognosis for a live birth after unexplained recurrent implantation failure following IVF\/ICSI","volume":"34","author":"Koot","year":"2019","journal-title":"Hum Reprod"},{"key":"B9","doi-asserted-by":"publisher","first-page":"104429","DOI":"10.1016\/j.jri.2025.104429","article-title":"Association of anti-phosphatidylserine\/prothrombin antibodies with adverse in vitro fertilization outcomes","volume":"168","author":"Liu","year":"2025","journal-title":"J Reprod Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2013.4255","article-title":"Subclinical impairment of ovarian reserve in systemic lupus erythematosus patients with normal menstruation not using alkylating therapy","volume":"22","author":"Ma","year":"2013","journal-title":"J Womens Health (Larchmt)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.03.032","article-title":"A novel ELISA system for simultaneous detection of six subclasses of anti-phospholipid antibodies for prediction of thrombotic complications among SLE patients","volume":"133","author":"Nojima","year":"2014","journal-title":"Thromb Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/aji.12280","article-title":"Is superfertility associated with recurrent pregnancy loss","volume":"72","author":"Orlando","year":"2014","journal-title":"Am J Reprod Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/0004563216672248","article-title":"Antiphospholipid and antioangiogenic activity in females with recurrent miscarriage and antiphospholipid syndrome","volume":"54","author":"Pelusa","year":"2017","journal-title":"Ann Clin Biochem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2013.12.006","article-title":"What exactly do we mean by \u2018recurrent implantation failure\u2019? A systematic review and opinion","volume":"28","author":"Polanski","year":"2014","journal-title":"Reprod BioMed Online"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-013-8421-z","article-title":"Anti-phosphatidylserine\/prothrombin antibodies: an additional diagnostic marker for APS","volume":"56","author":"Pregnolato","year":"2013","journal-title":"Immunol Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1592336","article-title":"Pregnancy and antiphospholipid syndrome","volume":"42","author":"Schreiber","year":"2016","journal-title":"Semin Thromb Hemost"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12014","article-title":"Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities","volume":"10","author":"Sciascia","year":"2012","journal-title":"J Thromb Haemost"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2017-0502","article-title":"Antiphosphatidylserine\/prothrombin antibodies (aPS\/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome","volume":"56","author":"Shi","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13048-023-01174-6","article-title":"Relationship between thyroid antibody levels and ovarian reserve function in infertile chinese women with normal thyroid-stimulating hormone","volume":"16","author":"Sun","year":"2023","journal-title":"J Ovarian Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"101912","DOI":"10.1016\/j.jogoh.2020.101912","article-title":"Anti-phospholipid antibody may reduce endometrial receptivity during the window of embryo implantation","volume":"50","author":"Tan","year":"2021","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"B21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/humrep\/deh579","article-title":"ESHRE PGD Consortium \u2018Best practice guidelines for clinical preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS)\u2019","volume":"20","author":"Thornhill","year":"2005","journal-title":"Hum Reprod"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-006-0481-7","article-title":"Significance of antiprothrombin antibodies in patients with systemic lupus erythematosus: clinical evaluation of the antiprothrombin assay and the antiphosphatidylserine\/prothrombin assay, and comparison with other antiphospholipid antibody assays","volume":"16","author":"Tsutsumi","year":"2006","journal-title":"Mod Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.04.001","article-title":"Added value of antiphosphatidylserine\/prothrombin antibodies in the workup of obstetric antiphospholipid syndrome: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"21","author":"Vandevelde","year":"2023","journal-title":"J Thromb Haemost"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e13621","DOI":"10.1111\/aji.13621","article-title":"Antiphosphatidylserine\/prothrombin antibodies (aPS\/PT) and risk of obstetric anti-phospholipid syndrome","volume":"89","author":"Zhang","year":"2023","journal-title":"Am J Reprod Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2172-15-11","article-title":"Serologic autoimmunologic parameters in women with primary ovarian insufficiency","volume":"15","author":"Zhen","year":"2014","journal-title":"BMC Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"975704","DOI":"10.1155\/2015\/975704","article-title":": anti-phosphatidylserine\/prothrombin antibodies are associated with adverse pregnancy outcomes","volume":"2015","author":"\u017digon","year":"2015","journal-title":"J Immunol Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.autrev.2015.01.012","article-title":"The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study","volume":"14","author":"Mekinian","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B29","doi-asserted-by":"publisher","first-page":"101463","DOI":"10.1016\/j.berh.2019.101463","article-title":"Antiphospholipid syndrome","volume":"34","author":"Sammaritano","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez419","article-title":"et al: Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry","volume":"59","author":"Alijotas-Reig","year":"2020","journal-title":"Rheumatol (Oxford)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1731905\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:44:20Z","timestamp":1768977860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1731905\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1731905"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1731905","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"article-number":"1731905"}}